CROI 2017 Abstract e-Book

Abstract eBook

Poster and Themed Discussion Abstracts

treatment (SVRS12). Secondary endpoints: Safety (percentage of withdrawal due to toxicity and/or hepatic decompensation) and efficacy according to regimen used and HCV genotype. Change in TE value after HCV treatment was also evaluated. Results: A total of 201 patients started treatment. Mostly, male (n=150; 74.3%), Caucasian (n=198; 98%) and ex-IDUs (n=165; 81.7%). Genotypes: Gt-1a, 75 (37.1%); Gt-1b, 27 (13.4%); Gt-4, 51 (25.2%) and Gt-3, 38 (18.8%). Baseline median TE was 20.7KPa (IQR 16.1-33) and HCV-RNA log 10 6.1UI/mL (IQR 5.7-6.6). Most patients had Child-Pugh A class score (n=153; 75.7%) and 36 (17.8%) of them suffered prior hepatic decompensation. There were 104 (51.5%) pretreated patients, of whom 40.4% (n=42) with null response. SVR12 data was available in 170 (84.6%) patients. More commonly used regimens: SOF/LDV+RBV, 43 (25.3%) patients; SOF+SMV+RBV, 34 (20%); SOF/LDV, 26 (15.3%) and SOF+DCV+RBV, 25 (14.7%). Overall, 92.9% (158/170) of patients achieved SVR12, without differences between genotypes (Table 1). A significant lower SVR12 was observed in pretreated as compared to naive patients (88.8% vs. 97.5%; p=0.026). Causes of treatment failure were: 7 (4.1%) relapses, 2 (1.2%) lost to follow-up, 1 (0.6%) toxicity-related discontinuation, 1 (0.6%) hepatic decompensation and 1 (0.6%) viral breakthrough. RBV dose modification was needed in 20 (16.3%) cases, mainly due to anemia (n=17). On- treatment hepatic decompensation was seen in 4 (2.4%) patients (encephalopathy and ascites, 2 each). At week 12 after treatment, TE decreased a mean of 5.6 KPa (95%CI 1.8-9.2; p=0.004) as compared with baseline. Conclusion: In our cohort, 92.9% of cirrhotic HCV-HIV coinfected patients achieved SVR12, which was associated with a significant decrease in TE. Only 2 (1.2%) patients had to stop treatment due to adverse events.

Poster and Themed Discussion Abstracts

536 INFLUENCE OF HIV ON CHANGES IN LIVER FUNCTION IN CIRRHOSIS AFTER ANTI-HCV TREATMENT

Juan Macías 1 , Luis E. Morano-Amado 2 , Francisca Cuenca-Lopez 3 , Dolores Merino 4 , Manuel Márquez 5 , Karin Neukam 1 , Maria J. Rios-Villegas 6 , Francisco Téllez 7 , Juan A. Pineda 1 1 Hosp Univ de Valme, Sevilla, Spain, 2 Hosp Univ Alvaro Cunqueiro, Vigo, Spain, 3 Hosp Univ Reina Sofia, Cordoba, Spain, 4 Complejo Hospario Univ de Huelva, Huelva, Spain, 5 Hosp Virgen de la Victoria, Málaga, Spain, 6 Hosp Univ Virgen Macarena, Sevilla, Spain, 7 Hosp de La Línea, La Línea de la Concepción, Spain Background: In clinical trials with direct acting antivirals (DAA), improvements in liver function among individuals with cirrhosis have been found in up to two thirds of patients at SVR4. In real life, improvements in MELD score at SVR12 were detected less frequently. However, comparative data of liver function after SVR in patients with cirrhosis due to

CROI 2017 224